Indus Tower share price gains 4% on Board meeting updates to consider dividend, bonus, buyback
Stock Market Today: Indus Tower share price gained up to 4% in the morning trades on Monday, April 28. The gains for Indus Towers share price were led by the company's update on a Board Meeting, scheduled for April 30, that will consider various proposals such as dividend, bonus, and buyback.
Indus Towers, in its intimation to the National Stock Exchange of India (NSE) and the BSE Ltd on Sunday, April 27, gave updates about a board meeting to be held on Wednesday, April 30, 2025.
Indus Towers announced that the Board of Directors, at its meeting scheduled on Wednesday, April 30, 2025, shall, inter-alia, consider viable options and strategies for enhancing shareholder returns including through buy back, bonus by way of shares and/or debentures or dividend or any other permissible mode or instrument or any combination thereof.
Indus Towers also announced that the Trading Window for dealing in shares of the Company shall remain closed for all Designated Persons of the Company till Friday, May 02, 2025. The trading window shall be deemed to be closed in respect of the aforementioned purposes as well, in accordance with applicable laws.
Indus Towers share price opened at ₹ 409.05 on the BSE on Monday, and started gaining right from the time of start of the trading session. At the time of opening, Indus share price opened more than 3% higher than the previous day's closing price of ₹ 396.55.
Indus Towers' share price thereafter gained further to the intraday highs of ₹ 410.20 on the NSE and ₹ 409.40 on the BSE
Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
First Published: 28 Apr 2025, 09:38 AM IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
36 minutes ago
- Time of India
Top 15 Tier-2 cities see 6% growth in home sales value in Q1 2025
The value of residential properties sold across India's leading 15 tier 2 cities showed a 6% rise to Rs 40,443 crore during Q1 2025, compared to Rs 38,102 crore in Q1 2024. PropEquity, an NSE-listed property analytics firm, reported that Lucknow led the growth amongst tier 2 cities with a 25% increase, selling 1301 units in Q1 2025. Coimbatore followed with 21% growth, Gandhi Nagar with 18%, and Mohali with 2%. The total units sold decreased by 8% to 43,781 units in Q1 2025, down from 47,378 units in the corresponding period of the previous year. "The decline in sales in tier 2 cities in January-March period is in line with trends witnessed in tier 1 cities. However, lesser supply in this quarter resulted in lower sales in tier 2 cities. State Capitals performed relatively better," said Samir Jasuja, Founder and CEO, PropEquity according to an ET repport by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Brass Idols - Handmade Brass Statues for Home & Gifting Luxeartisanship Buy Now Undo Among the remaining 11 cities, sales declined in Q1 2025, with Visakhapatnam showing the steepest fall at 37%, whilst Ahmedabad and Goa experienced minimal declines of 1% each. Coimbatore achieved the highest increase in sales value at Rs 1120 crore in Q1 2025, representing 52% growth. Lucknow followed at 48%, Gandhi Nagar at 36%, whilst Mohali and Goa each grew by 17%. Ahmedabad and Bhubaneshwar both increased by 7%, and Kochi by 5%. Seven cities experienced declining sales values in Q1 2025, with Visakhapatnam showing the largest decrease at 35%, whilst Vadodara and Nagpur recorded the smallest declines at 1% each. "Demand in tier 2 cities, however, remains robust as people have shown greater preference for organised living. Urban rejuvenation efforts, improved connectivity & social infrastructure, and more importantly greater employment opportunities mainly in IT and new manufacturing hubs in tier 2 cities have further accelerated demand not only from within but also from people who have migrated to metro cities and are preferring to purchase property in their hometowns," Jasuja said. The six State Capitals - Gandhi Nagar, Jaipur, Bhubaneshwar, Lucknow, Goa and Bhopal - experienced a 5% reduction in sales but a 17% increase in sales value, comprising 25% of sales and 30% of sales value in Q1 2025.
News18
40 minutes ago
- News18
Block Trades Boost Jubilant Stocks: Ingrevia Soars 11%, FoodWorks Up 2.5%
Last Updated: Jubilant Block Deal: Shares of Jubilant Group companies rallied on June 13 following large block deals Jubilant Block Deal: Shares of Jubilant Group companies rallied on June 13 following large block deals, with market participants attributing the trades to promoter stake sales aimed at funding the group's upcoming acquisition of a strategic stake in Hindustan Coca-Cola Beverages (HCCB). Jubilant FoodWorks rose 2.5% on the NSE, while Jubilant Ingrevia surged over 11% as significant chunks of equity changed hands via block trades. According to exchange data, five block deals involving 1.06 crore shares — or 1.6% of Jubilant FoodWorks' equity — were executed. Meanwhile, six block trades in Jubilant Ingrevia saw 98.7 lakh shares (6.2% equity) change hands. In addition, Jubilant Pharmova witnessed a single block trade comprising 48 lakh shares, amounting to roughly 3% of its equity. The cumulative value of the block transactions across the three companies is estimated at Rs 1,896 crore, as per market sources. According to reports, the Bhartia family — promoters of the Jubilant Group — likely offloaded these stakes to partially fund their earlier-announced Rs 12,500 crore investment in Hindustan Coca-Cola Holdings (HCCH). In December, the group said it would acquire a 40% stake in HCCH via its subsidiary, Jubilant Beverages Ltd. HCCH is the parent company of HCCB, India's largest bottler for Coca-Cola. Jubilant FoodWorks operates the Domino's Pizza franchise across India, Nepal, Sri Lanka, and Bangladesh. It also manages Dunkin', Popeyes, and homegrown brands like Ekdum! and Hong's Kitchen. As of June 13, its market cap stood at around Rs 45,000 crore. Jubilant Pharmova, the group's pharma and life sciences arm, focuses on sterile injectables, contract research, allergy therapy, and radiopharmaceuticals. Its market capitalisation was Rs 17,760 crore. Jubilant Ingrevia operates in the life sciences and specialty chemicals segment, manufacturing products such as vitamin B3 and B4, pyridine derivatives, and ethanol. It also provides CDMO (contract development and manufacturing) services, with a market cap of nearly Rs 12,000 crore. First Published:
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Narayana, Max Healthcare shares gain up to 5%, hit new highs in weak market
Shares of hospitals and healthcare services providers were in demand, and rallied up to 5 per cent on the BSE in Friday's intra-day trade in an otherwise weak market on the back of a healthy outlook. Shares of Narayana Hrudayalaya hit a new high of ₹1,906.15, surging 5 per cent on the BSE in intra-day trade. The stock surpassed its previous high of ₹1,872.85 touched on April 21, 2025. The share price of Max Healthcare Institute also hit a new high of ₹1,234.70, gaining 3 per cent in intra-day trade. It surpassed its earlier high of ₹1,227.50 touched on January 8, 2025. Thyrocare Technologies (up 5 per cent at ₹1,028.90) and Krishna Institute of Medical Sciences or KIMS (up 3 per cent at ₹683.05) were up in the range of 3 per cent and 5 per cent. In comparison, the BSE Sensex was down 0.73 per cent at 81,096 at 02:01 PM. Most Indian hospitals have now broken even and started contributing to profits. There is a rising demand for specialized treatments, including oncology and high-end surgical procedures. This trend is contributing to higher ARPOB (Average Revenue per Occupied Bed) and overall revenue growth. According to analysts at Choice Equity Broking, accounting for ~5-7 per cent of revenue, medical tourism is expected to grow at nearly double the overall rate in the mid-term. Factors such as normalization in the geo-political issue, operationalization of a new airport in Noida, affordable treatment costs, world-class facilities, and skilled medical personnel will continue to attract international patients, particularly from Southeast Asia and the Middle East, analysts said. Meanwhile, India's healthcare sector is on the cusp of significant transformation, driven by increased public and private investments, policy initiatives, and demographic shifts. Despite the current challenges, including disparities in healthcare infrastructure and the availability of medical services in the workforce between urban and rural areas, the future looks promising with sustained efforts and strategic investments. As of 2022, India's healthcare spending accounted for 3.3 per cent of the GDP; however, with sustained efforts, it is anticipated to reach 5 per cent by 2030, according to CareEdge Ratings. Looking forward, the rising share of the population aged over 45 years, coupled with income growth, is also expected to catalyse higher demand for quality healthcare services. This demand will likely translate into sustained investments across the entire value chain, from medical education and training to hospital infrastructure and digital healthcare technologies, the rating agency said. As per latest available data from National Health Accounts (NHA), government healthcare spending has increased significantly in recent years. The government health expenditure (GHE) as a percentage of GDP grew from ~1.1 per cent in FY15 to ~1.8 per cent in FY22. Similarly, its share within the general government expenditure (GGE) saw a notable rise, climbing from ~3.9 per cent in FY15 to ~6.1 per cent in FY22. GHE as a percentage of total health expenditure (THE) grew from 40.8 per cent in FY18 to 48.0 per cent in FY22, demonstrating a shift toward government-funded healthcare. These trends highlight the government's growing commitment to strengthening the healthcare sector. Furthermore, per capita government health expenditure rose from ₹ 1,753 in FY18 to ₹ 3,169 in FY22 at a 16 per cent CAGR, indicating increased spending on healthcare services per individual, analysts at Elara Capital said in the Health Insurance sector update.
